IACP‘s Executive Vice President John Voliva, RPh, discusses the importance of office-use compounding for patients in an interview this week with D.C.-based publication, Inside Health Policy.

John Voliva, executive vice president of the International Academy of Compounding Pharmacists, says the final guidance, “Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act,” put limits on office-use compounding that go against congressional intent and should be rescinded.

“We’re asking for FDA to rescind it. It would be administrative from that standpoint, and then issue a proposed rule through the [Administrative Procedure Act] so we have notice and comment from the stakeholders on the public docket,” Voliva said to Inside Health Policy.

Read the entire article here.

Advertisements